Moderna reaches supply agreement with Gavi: 500 million doses in the pipeline for nations with less access

Moderna, the biotech company whose vaccine was recently listed for emergency use by the World Health Organization (WHO) for people 18 years of age and older, and who also plans on boosting its supply to 3 billion doses by next year, announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 vaccine, including an initial 34 million doses to be delivered in Q4 of this year. Through this agreement, on behalf of the COVAX Facility, Gavi also retains the option to acquire 466 million additional doses in 2022. All doses are offered at Moderna’s lowest tiered price.

This agreement covers the Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries—all 92 of them. COVAX is a global initiative co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO to certify fair access to Covid-19 vaccines for all countries, regardless of income level.

“I am grateful to our Gavi and COVAX partners for their tireless work and to the entire Moderna team for their collaboration to reach this agreement. This is an important milestone as we work to ensure that people around the world have access to our Covid-19 vaccine,” says Stéphane Bancel, Moderna’s CEO.